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Essentials
• Whether D-dimer at incident venous thromboembolism (VTE) can predict recurrence-risk is unknown.
• We explored this association in 454 cancer-free patients with a first lifetime VTE.
• A low D-dimer at first VTE diagnosis was associated with a low recurrence risk.
• The association was predominant in patients with deep vein thrombosis and unprovoked VTE.
Click to hear Dr Cannegieter's presentation on venous thrombosis: prediction of recurrence Summary. Background: Venous thromboembolism (VTE) is a common disease with a high recurrence rate. D-dimer measured after cessation of anticoagulant therapy predicts recurrence, and is used to decide on treatment prolongation. However, whether D-dimer measured at first VTE diagnosis can be used to assess recurrence-risk is unknown. Aims: To investigate the association between D-dimer, measured at first VTE diagnosis and risk of recurrent VTE. Methods: Information on clinical risk factors and laboratory markers were collected in 454 cancer-free patients with a first VTE. Recurrent VTEs and deaths during follow-up (1994-2012) were recorded. Results: During a median follow-up of 3.9 years, 84 patients experienced a recurrent VTE. The crude recurrence rate was 1.7 (95% confidence interval [CI], 1.0-2.9) per 100 person-years in the lower quartile of D-dimer (≤ 1500 ng mL
À1
), and 4.9 (95% CI, 3.9-6.1) per 100 person-years in the upper three quartiles combined, yielding an absolute risk difference of 3.2 per 100 person-years. Patients with D-dimer ≤ 1500 ng mL À1 had 54% lower recurrence-risk than patients with D-dimer > 1500 ng mL À1 (HR, 0.46; 95% CI, 0.25-0.82). The association was particularly pronounced among patients with unprovoked events and deep vein thrombosis, showing a 66% (HR, 0.34; 95% CI, 0.15-0.74) and 68% (HR, 0.32; 95% CI, 0.14-0.71) lower recurrence risk among patients with D-dimer ≤ 1500 ng mL À1 , respectively. Conclusions: A low D-dimer (≤ 1500 ng mL À1 ) measured at first VTE diagnosis was associated with
Introduction
Venous thromboembolism (VTE), a conceptual term for deep vein thrombosis (DVT) and pulmonary embolism (PE), is a serious disease that recurs in up to 30-40% of patients within 10 years following the first event [1] [2] [3] [4] [5] . Recurrent events can be effectively prevented through secondary prophylaxis with anticoagulants [6, 7] , although at the cost of an increased risk of bleeding [8] . The challenge therefore lies in identifying patients who may benefit from extended thromboprophylaxis, but with minimal risk of bleeding complications. Likewise, to avoid unnecessary exposure to bleeding risk, it is desirable to identify subjects with low risk of VTE recurrence in whom short-term treatment with anticoagulants would be sufficient. D-dimer, a global biomarker of coagulation activation and fibrinolysis, is commonly used in clinical algorithms for the diagnostic work-up of patients with suspected VTE [9, 10] . Several studies have shown that elevated D-dimer levels measured during or after cessation of anticoagulant therapy are associated with increased risk of recurrence in patients with unprovoked VTE [11] [12] [13] and are therefore regularly applied to assess individual recurrence risk and guide decisions on treatment prolongation [14] [15] [16] [17] . However, this strategy is resource demanding both for the patient and the healthcare system because of additional blood sampling and outpatient clinic visits for evaluation of recurrence risk. Information on D-dimer is widely available for most VTE patients at the time of diagnosis. Therefore, there is a clinical rationale to explore whether D-dimer, measured at the time of first VTE diagnosis (i.e. before initiation of anticoagulant therapy), can be used to distinguish between patients at high and low risk of recurrence. Our hypothesis was that low plasma D-dimer concentration at VTE diagnosis could identify subjects at low risk of recurrence. Therefore, we aimed to investigate the association between D-dimer, measured at the time of the first VTE diagnosis, and risk of recurrent VTE.
Methods

Study population
The source population comprised subjects participating in ≥ 1 of the six currently conducted surveys of the Tromsø study (hereby referred to as Tromsø 1-6), who were still alive and living in Tromsø by 1 January 1994 (n = 33 885). The Tromsø study is a single-center, population-based prospective cohort study, with repeated health surveys of inhabitants in Tromsø, Norway. Detailed information about the Tromsø study can be found elsewhere [18] . The study was approved by the Regional Committee of Medical and Health Research Ethics, and all participants gave their informed written consent. The overall attendance rates were high, ranging from 85% in Tromsø 2 to 66% in Tromsø 6, with an average of 78.5% for the six surveys.
Participants were followed from the date of inclusion in 1994 through to the end of the study on 31 December 2012. All potential cases of first lifetime VTE during follow-up were identified by searching the hospital discharge diagnosis registry, the autopsy registry and the radiology procedure registry at the University Hospital of North of Norway (UNN), which is the exclusive provider of all in-and outpatient VTE-related diagnostic procedures and VTE-related healthcare in the Tromsø region. Trained personnel reviewed the medical records for each potential VTE case and extracted information for case validation, as well as information on clinical risk factors and laboratory markers, using standardized forms. A VTE event was considered verified and recorded when presence of clinical signs and symptoms of DVT or pulmonary embolism were combined with objective confirmation tests (compression ultrasonography, venography, spiral computed tomography, perfusion-ventilation scan, pulmonary angiography or autopsy) and resulted in a VTE diagnosis that required treatment, as previously described [19] . Applying these criteria, we identified 822 subjects with a thoroughly validated first lifetime VTE diagnosis. D-dimer has low specificity for the diagnosis of VTE as it is often elevated in conditions such as malignancy, infections or inflammatory states [20] [21] [22] . Consequently, we excluded VTE patients with active cancer (n = 124) and patients already hospitalized for other conditions when the VTE occurred (n = 158). Moreover, patients with missing D-dimer values (n = 86) were excluded, which left us with 454 included VTE patients in our study.
Patient characteristics
Information on clinical and provoking factors at the time of and 8 weeks preceding the VTE event was obtained for all eligible patients. The VTE event was classified as provoked if preceded by (i) major surgery, trauma or an acute medical condition (acute myocardial infarction, ischemic stroke or major infectious disease) within 8 weeks prior to the event, (ii) marked immobilization (confinement to bed >3 days, confinement to wheelchair or long-distance travel exceeding 4 hours within the last 14 days prior to the event) or (iii) any other factor specifically described in the medical records to have provoked the VTE (e.g. intravascular catheter). If no provoking factor could be identified, the VTE was classified as unprovoked.
Clinical risk factors included were obesity, family history of VTE, use of estrogens, pregnancy, puerperium or other co-morbidities. The classification of obesity was made according to the definition from the World Health Organization (BMI > 30 kg m
À2
) [23] . Family history of VTE was defined as having a first-degree relative who suffered from a VTE before the age of 60 years. Co-morbidity was defined as having a myocardial infarction or a stroke within the last 12 months preceding the VTE, chronic obstructive pulmonary disease, myeloproliferative disorders, systemic lupus erythematosus (SLE) or chronic infection.
D-dimer measurements
D-dimer levels were assessed as part of the diagnostic work-up of patients with suspected VTE, and a negative test was defined as a D-dimer value < 500 ng mL
À1
. All blood samples were analyzed at the Department of Clinical Chemistry at the University Hospital of North Norway. In the period 1994-98 the NycoCard D-Dimer (Nycomed Pharma, Oslo, Norway) assay, based on the immunometric flow-through principle, was used to assess D-dimer. In the remaining period (1998-2012) D-dimer was assayed with the STA
Stago (Diagnostica Stago, Asnie eres, France). This test quantitatively measures D-dimer levels by the immunoturbidimetric method (liquid reagent).
Outcome registration of recurrent VTE and deaths
All recurrent VTE events during follow-up in the period 1994 through to 2012 were identified and validated using the same criteria as described for the validation of first lifetime VTE events. Information on mortality was obtained from the Norwegian Population Registry.
Statistics
For analyses of recurrence, subjects were followed from the date of their first VTE to the first occurring event of either recurrent VTE, death or loss to follow-up as a result of migration, or end of follow-up (31 December 2012). The study population was divided into quartiles based on D-dimer levels (quartile 1, ≤ 1500 ng mL À1 ; quartile 2, 1600-3000 ng mL À1 ; quartile 3, 3100-7000 ng mL
À1
; quartile 4, ≥ 7100 ng mL À1 ). Crude incidence rates (IRs) of recurrent VTE were calculated across categories of D-dimer and expressed per 100 person-years at risk. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). In the analysis across quartiles of D-dimer, the highest quartile was set as the reference. To test our hypothesis that low levels of D-dimer could identify patients at low risk of recurrence, we dichotomized the D-dimer variable by merging the upper three quartiles and used this upper category as the reference group. The HRs were estimated in two models; the first was adjusted for age and sex, and the second was additionally adjusted for duration of anticoagulant treatment. The proportional hazards assumption was tested for all variables using Shoenfeld residuals. Cumulative incidences were calculated and visualized in 1-Kaplan-Meier (1-KM) plots, both for overall VTE and in subgroups of VTE (i.e. among provoked and unprovoked first VTE events, and among first DVTs and PEs). In analyses according to clinical presentation, patients were classified as having isolated DVT or PE (with or without concurrent DVT).
In the presence of competing risk by death the cumulative incidence of recurrence is dependent on both the hazard of VTE and the hazard of death, and consequently the 1-KM is often overestimated in the regular analyses [24] [25] [26] . In order to evaluate the influence of the competing risk by death, sub-distribution hazard ratios (SHRs) and cumulative incidence functions (CIFs) were performed and visualized for overall VTE recurrence using the stcrreg and the stcrreg cif curve commands in Stata. All statistical analyses were performed using Stata version 14.0 (Stata Corporation LP, College Station, TX, USA).
Previous studies have shown that women with estrogen-related VTE and patients with distal DVT have a low risk of recurrence [16, [27] [28] [29] [30] . As these conditions may also be associated with low D-dimer levels, we performed sensitivity analyses in patients without estrogen-associated VTE, as well as in patients with proximal DVT, in order to rule out potential confounding by such low-risk groups.
Results
Baseline characteristics and distribution of risk factors according to quartiles of D-dimer are presented in Table 1 . Compared with the upper three quartiles, subjects in the lowest quartile tended to be younger and more likely female, and a slightly higher proportion were obese. Additionally, patients in the lowest quartile tended to be treated with anticoagulants for a shorter duration of time (< 6 months) than patients in the upper three quartiles. Co-morbidities and acute medical conditions were less common among patients with a D-dimer in the lowest quartile.
Of the 454 eligible patients with a validated first lifetime VTE, 84 patients experienced a recurrent VTE event during a median of 3.9 years of follow-up. Crude recurrence rates and hazard ratios of recurrent VTE according to quartiles of D-dimer are presented in Table 2 . Compared with quartile 4, patients with a D-dimer value in quartile 2 (HR, 0.88; 95% CI, 0.50-1.58) and quartile 3 (HR, 1.00; 95% CI, 0.56-1.57) had a similar risk of recurrence, whereas patients with a D-dimer below 1500 ng mL À1 had a 55% lower risk of recurrence (HR, (Fig. 1B) , the 10-year cumulative incidence estimate of recurrence dropped by almost 10% in the upper three quartiles (quartile 2: 24.2%, quartile 3: 26.2% and quartile 4: 24.8%), whereas it remained essentially unchanged in patients with a D-dimer in the lowest quartile (14.1%). Analyses restricted to the time after termination of anticoagulant therapy produced similar results ( Figure S2 ). Risk estimates of recurrent VTE according to a D-dimer cut-off of ≤ 1500 ng mL À1 , for overall VTE and in subgroups of VTE patients, are shown in Table 3 . For overall VTE, the crude incidence rate was 1.7 (95% CI, 1.0-2. (Table 3) . Additional adjustment for duration of anticoagulant treatment had negligible effect on the risk estimates (Table 3 , Model 2). Cumulative incidence of VTE recurrence according to quartiles of D-dimer in patients with unprovoked VTE and DVT are shown in Fig. 2 . Among patients with unprovoked VTE, a similar pattern to that for overall VTE was observed ( Fig. 2A) 
4).
In quartile 1, the 1-and 5-year cumulative incidences of recurrence were 1.4% (95% CI, 0.2-9.3) and 10.5% (95% CI, 5.1-20.9), respectively. Among patients with DVT, the 10-year cumulative incidence of recurrence ranged from 14.6% (95% CI, 7.1-28.7) among patients with a D-dimer value below 1500 ng mL À1 to 51.3% (95% CI, 31.5-74.6) in patients with a D-dimer ≥ 7100 ng mL À1 (Fig. 2B) . In subjects with provoked VTE and PE, the cumulative incidence of recurrence was essentially similar to that of overall VTE in those with D-dimer ≤ 1500 ng mL À1 (16.7% and 13.6%), but the effect across quartiles was not as consistent as for unprovoked VTE and DVT ( Figure S1 ). Analysis restricted to patients without estrogen-related VTE and analysis of patients with proximal DVT showed similar results (Table S1) .
Discussion
In the present study, we investigated whether D-dimer measured at the time of VTE diagnosis, before initiation of anticoagulant therapy, was associated with risk of recurrence. We found that subjects with a D-dimer value ≤ 1500 ng mL À1 had a substantially lower risk of VTE recurrence compared with patients with a D-dimer > 1500 ng mL
À1
. The overall incidence rate of recurrence was 1.7 per 100 person-years in those with D-dimer ≤ 1500 ng mL À1 , and the 10-year cumulative incidence was 14%. The association between low D-dimer and recurrence was particularly pronounced among patients with incident DVT and in patients with a first unprovoked VTE event, who had a 69% and 64% lower risk of recurrence, respectively. The corresponding absolute risk differences were 4.1 and 3.5 per 100 persons per year. Our findings suggest that a low D-dimer measured at the time of VTE diagnosis may aid decisions on short-term treatment, particularly in patients with unprovoked VTE. However, our findings need to be confirmed in additional observational studies and tested in clinical randomized studies.
To our knowledge, no previous study has investigated the association between D-dimer measured at the time of VTE diagnosis and the risk of recurrent events. In THE-VTE study [31] , patients with an elevated D-dimer level (> 500 ng mL À1 ), measured 2-3 months after discontinuation of anticoagulation, had a more than 2-fold higher risk of recurrence than patients with a normal D-dimer level, and the absolute recurrence rate was 1.8 per 100 person-years in those with normal D-dimer. In a cohort of 610 VTE patients [32] , D-dimer levels measured shortly after discontinuation of anticoagulant therapy were related to risk of recurrence, with the risk being 40% and 70% reduced in patients with a D-dimer in the range CI, confidence interval; HR, hazard ratio; IR, incidence rate. *Per 100 person-years. †HRs are adjusted for age and sex. ‡HRs are adjusted for age, sex and duration of anticoagulant treatment.
250-750 ng mL À1 and < 250 ng mL À1 , respectively, as compared with patients with a D-dimer ≥ 750 ng mL À1 .
Furthermore, a 2.6-fold increased risk of recurrence was found for patients with elevated compared with normal Ddimer in a patient level meta-analysis investigating the ability of D-dimer to assess recurrence risk after unprovoked VTE [13] . The annualized recurrence rates ranged from 2.0 to 4.2, and from 7.4 to 10.2, per 100 for those with normal compared with elevated D-dimer, respectively [13] . In the PROLONG study [33] , elevated D-dimer measured 1 month after discontinuation of treatment was associated with a 2.5-fold increased risk of adverse outcomes (recurrent VTE or major bleeding), and the absolute rates were 4.4 and 10.9 per 100 person-years for patients with normal and elevated D-dimer, respectively. Current treatment guidelines for VTE recommend at least 3 months of anticoagulant therapy [34] , with subsequent evaluation of the risk-benefit ratio for extended therapy in patients with unprovoked DVT or PE. Whether D-dimer levels measured 1 month after anticoagulation withdrawal can be used to select patients with unprovoked VTE who can stop anticoagulant therapy is debated [27] .
In our study, patients with a D-dimer level ≤ 1500 ng mL À1 measured in the acute phase of VTE had a low absolute risk of recurrence. Noticeably, the recurrence rates observed in the lowest D-dimer category in our study were similar to [31] or lower than [13, 33] the rates among patients with normal D-dimer (i.e. < 500 ng mL À1 ) in studies that measured D-dimer after treatment withdrawal. The absolute recurrence rates in those with D-dimer ≤ 1500 ng mL À1 were 1.7% at 1 year and 8.5%
at 5 years for overall VTE, and correspondingly 1.4% and 10.5% in those with unprovoked VTE. Of note, these rates are below the rates considered acceptable to justify stopping anticoagulation (5% at 1 year and 15% at 5 years) according to the recommendation from the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis [35] . However, because of limited statistical power in subgroups, some of the confidence intervals exceeded the upper limit of the recommended rates, and our findings should therefore be interpreted with some caution.
As information on D-dimer is widely available for most VTE patients at the time of diagnosis, the potential use of D-dimer to identify patients at low risk of recurrence may have great clinical utility for the initial decision on treatment duration and further follow-up of the patients. Current risk prediction models for VTE recurrence among patients with a first unprovoked VTE, such as the Vienna prediction model [16] , the DASH prediction rule [15] and the Men continue and HER DOO2 rule [17] , all make use of D-dimer measurements during or after anticoagulation, together with clinical predictors, to distinguish patients at high and low risk of recurrence. The clinical elements included in these rules can usually be assessed at the initial patient examination. Thus, if D-dimer assessment before start of anticoagulation can be utilized in similar upcoming prediction models to identify patients at low risk of recurrence, it may prove valuable for both clinicians and patients. For the clinicians, it may provide the opportunity to make decisions on treatment duration upon hospital discharge, and reduce the need for additional outpatient care after discontinued treatment. For the patients, information on the prognosis of the disease may provide well-appreciated reassurance and, as the need for additional blood sampling is reduced, the patients will be less subjected to additional discomfort.
Women with estrogen-related first VTEs and patients with distal DVT have previously been shown to have a low risk of recurrence [16, [27] [28] [29] [30] . To investigate whether the observed association could be driven by such low-risk patient groups, we performed separate analyses excluding women with estrogen-associated first VTEs, as well as analysis restricted to patients with proximal DVT. The results of these sub-studies were essentially similar to those of the overall analysis and analysis of all DVT patients, respectively. Furthermore, neither adjustment for duration of anticoagulant treatment nor analysis of the cumulative incidence with and without death as a competing event after cessation of anticoagulant treatment noticeably altered the results.
Recruitment of VTE patients from a general population, high attendance rates, prospective design and longterm follow-up are among the main strengths of the present study. Furthermore, all VTE-related health care in the municipality of Tromsø is provided by a single hospital, which together with comprehensive case validation through a multimodal approach, firm criteria and extensive review of medical records, enhances the probability of a complete and accurate VTE register. The study also has some limitations. Around 16% of the eligible patients were excluded because of missing D-dimer values. However, patient characteristics and incidence rates of recurrence were essentially similar in those with and without missing values of D-dimer, indicating that the missing value was presumably at random, and thereby would not be likely to introduce selection bias. Second, two different assays were used to assess D-dimer levels during the study period. Although the Sta-Liatest has consistently reported excellent analytical properties [36] [37] [38] , there are conflicting results regarding the NycoCard D-dimer assay. However, the majority of the D-dimer measurements were assessed using the Sta-Liatest (Diagnostica Stago Ò ) and when we restricted our analysis to include only measurements from the validated Sta-Liatest (Diagnostica Stago Ò ) the results remained essentially the same (data not shown). It is therefore unlikely that comprehensive misclassification has occurred as a result of the poor analytical properties of the NycoCard D-dimer assay. Unfortunately, we did not have information on postanticoagulation D-dimer values in our study. Thus, we could not assess whether patients with a low D-dimer at the time of first VTE diagnosis had a negative D-dimer (< 500 ng mL À1 ) after anticoagulation.
In conclusion, a low D-dimer (≤ 1500 ng mL À1 ) measured at the time of first VTE diagnosis identified a quarter of the patients as having a low risk of recurrence. The association was particularly pronounced among patients with a first unprovoked event and in patients with DVT. Our findings suggest that D-dimer, measured at VTE diagnosis, may be used to identify VTE patients at low risk of recurrence and guide decisions on short-term anticoagulation in these patients. Further studies are needed to confirm our findings and to investigate whether D-dimer, measured at the time of first VTE diagnosis, could replace or improve the contemporary use of post-anticoagulation D-dimer measurements in existing prediction models.
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